ACHV - Achieve Life Sciences Inc

https://www.achievelifesciences.com

Momentum: Bearish

Recent News

Why Is Achieve Life Sciences Stock Skyrocketing Thursday? - Achieve Life Sciences ( NASDAQ:ACHV )

Benzinga • 3 weeks, 3 days ago • score: 0.27

FDA submission backed by two Phase 3 trials showing higher abstinence rates. HC Wainwright sets $12 target, citing an undervalued stock and $13 billion market. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here → Achieve Life Sciences Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.

52W High

$5.31

52W Low

$1.84

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.54

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.42

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

4.02

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

3.81%

Institutions (25–75% balanced)

61.44%

Shares Outstanding

51,105,000

Float

42,333,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.48

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.20%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1284

0.1325

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025